$EAF

GrafTech International (EAF) to Release Earnings on Friday

GrafTech International (EAF) is scheduled to release its Q1 2026 earnings before market open on Friday, May 1st, with analysts expecting a loss of ($1.3033) per share and revenue of $120.667 million. The company missed previous estimates and analysts project continued losses for the current and next fiscal year, rating the stock as "Reduce" with a target price of $11.75. Shares are currently trading around $9.55, and institutional investors hold a significant portion of the company's stock.

Original reporting
MarketBeat · MarketBeat
Published Apr 24, 2026, 5:35 AM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Apr 24, 2026, 6:31 AM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
GrafTech International (EAF) to Release Earnings on Friday — source image
Decision brief

The 30-second read

$EAFBearishMed
01

Why it matters

The upcoming earnings are likely to confirm ongoing challenges, leading to further downside risk.

02

Market read

EAF's earnings report is a significant event for traders and investors focused on manufacturing stocks, with potential for short-term volatility.

03

What to watch

Potential for short-term volatility; broader market trends and macroeconomic factors could influence stock movement beyond earnings results.

Timing: High, as earnings are scheduled for May 1st before market open.

Background

GrafTech International has a history of missing earnings estimates, and current analyst sentiment is bearish.

Company-level read

Ticker impact

$EAFBearishMedium confidence
Context

High relevance due to upcoming earnings report and analyst sentiment.

Expected impact

Potential short-term decline post-earnings, with possible stabilization or rebound depending on future guidance.

Evidence & confidence

The earnings miss and bearish analyst sentiment suggest downward pressure. However, market reaction may vary based on guidance and broader market conditions.

Market effects

Manufacturing and industrial sectors may experience slight negative sentiment due to EAF's earnings outlook.

Limited regional impact; primarily affects investors and stakeholders in North America.

Low; EAF's earnings are unlikely to influence global markets significantly.

Counterpoint

If EAF surprises positively with guidance or better-than-expected earnings, the stock could rebound, presenting a buying opportunity.

Key entities

  • GrafTech International

    A manufacturer of graphite electrodes and related products.

  • Analysts

    Market analysts projecting earnings and revenue estimates.

Related articles

$EAFMed

GrafTech and Antora Energy Partner to Power American Industry with Carbon

GrafTech (NYSE: EAF) and Antora Energy have partnered to develop carbon-based materials for Antora's thermal batteries, utilizing GrafTech's St. Marys facility. The collaboration aims to lower energy costs and strengthen domestic manufacturing, creating jobs and diversifying GrafTech's end markets. Antora recently raised $550 million in a Series C funding round and commissioned a large battery storage project.

$EAFMed

GRAFTECH INTERNATIONAL LTD (EAF): Results of Operations and Financial Condition

GRAFTECH INTERNATIONAL LTD (EAF) filed an SEC Form 8-K — Results of Operations and Financial Condition. EX-99.1 2 a2026-2qearningspressrelea.htm EX-99.1 Document EXHIBIT 99.1 GrafTech Reports Second Quarter 2026 Results Delivering Strong Sales Volume Growth Reaffirming Full-Year Volume and Cost Expectations Executing Pricing Actions and Other Strategic Initiatives to Improve Profit

$DFTXLow

Definium Therapeutics to Discuss Topline Results from Phase 3 Panorama Study in Generalized Anxiety Disorder on September 14, 2026

Definium Therapeutics (DFTX) will host a webcast on September 14, 2026, to discuss topline results from its Phase 3 Panorama study of DT120 ODT for generalized anxiety disorder. The study enrolled 245 participants across 32 centers, with primary endpoints focused on changes in HAM-A and CGI-S scores. Definium Therapeutics is a Nasdaq-listed biopharmaceutical company developing psychiatric and neurological disorder treatments.